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with increase carotid intima-media thickness
Huocheng Liao1, Zhiming Li2, Dongdan Zheng3, Jianping Liu1, Yan Liu1, Chun Xiao1 and Hongguang Wang4*Abstract
Background: High sensitivity C-reactive protein (Hs-CRP) and adiponectin (APN) are two critical cytokines and exert
inverse effects on atherosclerosis initiation and progression. The purpose of our study was to investigate the value
of Hs-CRP and ANP ratio (Hs-CRP/APN ratio) on evaluating atherosclerosis progression.
Method: One hundred sixty consecutive participants underwent carotid intima-media thickness (CIMT) measured
by ultrasound were enrolled and drawn fasting blood samples for plasma levels Hs-CRP and APN, serum levels
of lipid profiles and fasting blood glucose evaluation. Other anthropometrics and clinical status were collected
by questionnaire. All participants were divided into 4 groups according to the baseline Hs-CRP/APN ratio and
underwent CIMT measurement every 6 months. CIMT increment and composite cardiovascular endpoints were
compared after 24 months’ follow-up.
Results: At baseline, body mass index (BMI), smoking, diabetic mellitus, usage of statins, Hs-CRP and APN
independently correlated with Hs-CRP/APN ratio as analyzed by spearman rank correlation. Smoking, serum level
of LDL-C, plasma level of Hs-CRP and Hs-CRP/APN ratio were positively correlated with CIMT while usage of statins
and plasma level of APN were negatively correlated with CIMT as analyzed by multiple linear regression analysis.
After 24 months’ follow-up, the progression of CIMT was the most prominent in the fourth quartile of baseline
Hs-CRP/APN ratio. In addition, the incidence of composite cardiovascular endpoint was also higher in the fourth
quartile as compared to the other 3 lower quartiles.
Conclusion: Hs-CRP/APN ratio was a useful predictor to discriminate subjects who were at increased risk of
atherosclerosis progression.
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In the past decades, accumulating evidence from basic
and clinical studies consistently demonstrate that inflam-
mation plays pivotal and complicated roles in the initiation
and progression of atherosclerosis and atherosclerotic
cardiovascular diseases [1-3]. Notably, increased serum
level of inflammatory cytokines portends a higher inci-
dence of cardiovascular events such as myocardial infarc-
tion and ischemic stroke [4,5]. Therefore, guidelines have
recommended that inflammatory cytokines such as high
sensitivity C-reactive protein (Hs-CRP) should be inte-
grated into the algorithm of cardiovascular risk evaluation* Correspondence: guang99@vip.sina.com
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unless otherwise stated.[1,6]. Knowingly, Hs-CRP is a non-specific inflammatory
cytokine, and by means of increasing inflammatory cells
infiltration, augmenting oxidative stress, impairing endo-
thelial function as well as decreasing nitric oxide (NO)
production, Hs-CRP accelerates the formation and dis-
ruption of atherosclerotic plaque [7-9]. On the contrary,
adiponectin (APN) is a cardio-protective cytokine due to
its capability to inhibiting inflammatory cytokines such as
interleukin-6, TNF-α and Hs-CRP expressions, down-
regulating monocytes chemoattractant proein-1 (MCP-1)
expression, increasing NO generation as well as enhancing
myocardial blood perfusion [10-13].
Carotid intima-media thickness (CIMT), an early and
sensitive indicator for subclinical atherosclerosis, is signifi-
cantly associated with plasma levels of Hs-CRP and APN
as reported by previous studies [14,15]. With respect to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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APN exert on cardiovascular system, we hypothesized that
Hs-CRP and APN ratio (Hs-CRP/APN ratio) might be
useful as an indicator to help us discriminate the status of
atherosclerosis. Thus that, we conducted a pilot study to
investigate the relationship between Hs-CRP/APN ratio
and CIMT in population without overt cardiovascular
diseases, and then we consecutively measured CIMT in
the follow-up 24 months so as to determine the value of




One hundred and sixty consecutive subjects were ran-
domly enrolled from January 2011 to January 2012, and
all subjects were underwent CIMT measurement by du-
plex ultrasound. Written informed consent was obtained
and the ethics committee of the 3rd People’s Hospital of
Huizhou approved present study. Subjects who initially
without overt cardiovascular diseases, which defined as
angina pectoris, previous myocardial infarction, transient
ischemia attack or ischemic stroke and peripheral artery
diseases, were ruled in, and those with a previous history
of atherosclerotic cardiovascular diseases or baseline
level of Hs-CRP >10 mg/L, which indicated intensively
infectious diseases or collagen diseases or potential tu-
mors, were ruled out.
Demographic and clinical characteristics collection
Demographic and clinical characteristics such as age,
gender, body mass index (BMI), smoking status, hyper-
tension or current anti-hypertension therapy, dyslipi-
demia or use of lipid-lowering medications and diabetic
mellitus were obtained by the means of computerized
questionnaire.
Laboratory examination
Fasting blood samples were drawn from each participant
and transferred on ice to center laboratory for analysis.
An IMMAGE automatic immunoassay system (Beckmann-
Coulter) was used to examine plasma level of Hs-CRP.
Intra-assay variability coefficient lied between 3.5-5.0%, and
inter-assay variability coefficient between 4.0-7.5%, and
limited detection level was 0.2 mg/L. APN was measured
by a high sensitivity Human adiponectin ELISA kit (BioCat
GmbH) with intra-assay variability coefficient lied
between 4.0-5.5% and inter-assay variability coefficient
between 5.0-7.5%. Triglyceride (TG), total cholesterol
(TC), low density lipoprotein-cholesterol (LDL-C), high
density lipoprotein-cholesterol (HDL-C) and fasting
blood glucose were also measured by Automatic Bio-
chemistry Analyzer (Beckman coulter UniCel DxC 800
Synchron).Carotid intima-media thickness measurement
Ultrasonic examination was performed with an 8.5 MHz
linear array transducer. The initial and follow-up mea-
surements were performed by two investigators who
were blinded to the characteristics of all participants.
Common carotid artery (one milimeter below the
carotid artery bifurcation) was chosen to evaluate CIMT
on both sides. The average inter-observers reliability
coefficient was 0.95 (95% confidence interval (CI) 0.93
to 0.96, p < 0.05) and the intra-observer reliability co-
efficient 0.93 (95% CI 0.91 to 0.94, p < 0.05). The values
of CIMT were averaged by the left and right CIMT
values. The absolute annual change of CIMT was deter-
mined by the following formula: (final value minus base-
line value) divided by the total follow up years.
Clinical endpoints
All subjects were followed up for the occurrence of first
cardiovascular events, including myocardial infarction,
ischemic stroke, and cardiovascular diseases related
death. Total follow-up lasted for 24 months.
Statistical analysis
All analyses were performed by SPSS16.0 package. All
values were expressed as mean ± SD or percentage. Cor-
relation between Hs-CRP/APN ratio with demographic
and clinical characteristics were evaluated by Pearson
correlation or Spearman rank correlation as appropriate.
Independent correlation between Hs-CRP/APN ratio
and other variables with CIMT were determined by mul-
tiple linear regressions. Subjects were divided into four
groups according to the baseline quartiles of Hs-CRP/
APN ratio. Comparison of CIMT value of each quartile
at the same time point, and comparison of CIMT incre-
ment of each quartile during follow-up were operated by
one-way ANOVA. A p value < 0.05 was considered to be
significant difference.
Results
Baseline characteristics and relationship between Hs-CRP/
APN ratio and other variables
As shown in Table 1, the age of participants was 55.3 ±
4.8 years and 45.0% of participants were female. Approxi-
mately 58.1% were cigarette smoker, BMI was 26.5 ± 4.1
Kg/m2, 45.0% with diabetic mellitus, 53.1% with hyperten-
sion and nearly 51.9% with anti-hypertension therapy,
current statins usage were 49.3%. Plasma levels of Hs-CRP
and APN were 6.9 ± 1.8 mg/L and 10.8 ± 2.2 μg/L, respec-
tively, and the Hs-CRP/APN ratio was 0.6 ± 0.2. Corre-
lation between Hs-CRP/APN ratio and other variables
was shown in Table 1. For all the variables, BMI, smoking,
diabetic mellitus, usage of statins, and plasma levels of
Hs-CRP and APN significantly correlated with Hs-CRP/
APN ratio (all p values < 0.05).
Table 1 Baseline characteristics and relationship between
Hs-CRP/APN ratio and other variables (n = 160)
Variables Mean ± SD or percentage r P
Age (years) 55.3 ± 4.8 0.21 0.34
Female (%) 72 (45.0) 0.18 0.65
BMI (Kg/m2) 26.5 ± 4.1 0.43 <0.05
Smoking (%) 93 (58.1) 0.72 <0.05
Diabetic mellitus (%) 72 (45.0) 0.34 <0.05
Hypertension (%) 85 (53.1) 0.58 0.15
TG (mmol/L) 1.5 ± 0.5 0.33 0.13
TC (mmol/L) 5.6 ± 0.4 0.26 0.25
HDL-C (mmol/L) 1.6 ± 0.7 0.25 0.16
LDL-C (mmol/L) 4.3 ± 0.8 0.35 0.08
Usage of statins (%) 79 (49.3) −0.67 <0.05
Anti-hypertension 83 (51.9) −0.24 0.78
Hs-CRP (mg/L) 6.9 ± 1.8 0.79 <0.001
APN (μg/L) 10.8 ± 2.2 −0.83 <0.001
Hs-CRP/APN ratio 0.6 ± 0.2
Spearman’s rank correlation coefficient (r) is shown.
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other variables
Relationship between CIMT and Hs-CRP/APN ratio and
other variables was shown in Table 2. Notably, CIMT
significantly correlated with smoking, serum level of
LDL-C, usage of statins, plasma levels of Hs-CRP and
APN, and Hs-CRP/APN ratio. Specifically, usage of

















Hs-CRP/APN ratio 0.53 0.02
β standard regression coefficient.correlated with CIMT (p < 0.05), and other variables
including smoking, serum level of LDL-C, plasma level
of Hs-CRP and Hs-CRP/APN ratio were positively
correlated with CIMT (p < 0.05).
Comparison of CIMT within quartiles of Hs-CRP/APN ratio
According to baseline Hs-CRP/APN ratio, participants
were divided into four quartiles. Hs-CRP/APN ratio from
the first to the fourth quartile was 0.10 ± 0.03, 0.34 ± 0.06,
0.50 ± 0.10 and 0.68 ± 0.13, respectively. As presented in
Table 3, CIMT was significantly different between each
quartile at the same time point and the increment of
CIMT in the fourth quartile was the greatest when
compared to the other 3 groups.
Comparison of clinical events
During the 24 months’ follow-up, there were totally 4
cases of myocardial infarction and 6 cases of ischemic
stroke occurred. Notably, the incidence of composite
endpoint was higher in the fourth quartile (6 cases) than
the other 3 groups as shown in Table 4. In the fourth
quartile, the first episode of clinical event happened in
the first ten month, while it was in the eighteenth
month when the first clinical event occurred in the first
quartile.
Discussion
Our present study shows that in participants without
overt atherosclerotic cardiovascular diseases, increased
baseline Hs-CRP/APN ratio portends a higher risk of
CIMT progression and a higher incidence of cardiovas-
cular events during 24 months follow-up. Future study
is imperative in investigating whether decreasing Hs-
CRP/APN ratio could result in better cardiovascular
outcomes.
Previously, a substantial number of studies have reported
the association between cardiovascular risk factors and
plasma levels of Hs-CRP and APN. For example, BMI was
reported positively correlated with Hs-CRP level while
negatively with APN level [15,16], which therefore might
partially explain the positive relationship between BMI
and Hs-CRP/APN ratio in our current study. Smoking
is a crucial risk factor contributing to continuous sys-
temic inflammation due to its effects on impairing
endothelial function and promoting vascular inflamma-
tion [17]. Commonly, in population with long-term
cigarette smoking, the plasma level of Hs-CRP was
increased therefore resulting in the increased Hs-CRP/
APN ratio. Accordingly, most of the complications of
diabetes mellitus resulted from endothelial dysfunction
and activation [18,19], which characterized by reduced
NO production and inflammatory cytokines up-
regulation and subsequently leaded to plasma levels of
Hs-CRP increase and APN decrease. Previously, many
Table 3 Comparison of CIMT within quartiles of Hs-CRP/APN ratio
CIMT (mm) 1st (n = 40) 2nd (n = 40) 3rd (n = 40) 4th (n = 40) P
Baseline 0.65 ± 0.14 0.67 ± 0.11 0.70 ± 0.17 0.72 ± 0.15# < 0.05
6 months 0.66 ± 0.13 0.69 ± 0.15 0.72 ± 0.12 0.73 ± 0.14# < 0.05
12 months 0.68 ± 0.10 0.72 ± 0.11 0.74 ± 0.14 0.76 ± 0.19# < 0.05
18 months 0.70 ± 0.11 0.74 ± 0.20 0.77 ± 0.18 0.81 ± 0.18# < 0.05
24 months 0.71 ± 0.14 0.77 ± 0.19* 0.79 ± 0.16* 0.86 ± 0.20*# < 0.001
P 0.145 < 0.05 < 0.05 < 0.001
Denote: 1st = the first quartile, 2nd = the second quartile, 3rd = the third quartile, and 4th = the fourth quartile; *P < 0.05, versus baseline level of CIMT at the same
quartile, #P < 0.05, versus the first quartile of CIMT at the same time point.
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tropic effects of statins, which was largely ascribed to
the reduction of Hs-CRP level and increase NO produc-
tion [20,21]. Therefore, it was no wonder that statins
was negatively correlated with Hs-CRP/APN ratio.
However, In the future, to assess whether modifying
above factors could result in a favorable Hs-CRP/APN
ratio is imperative.
Carotid intima-media thickness (CIMT) has been
broadly considered an important parameter to identify
an early status of atherosclerosis, and measure of CIMT
could facilitate physicians to discriminate those who are
at increased risk of cardiovascular events [22,23]. In
current study, smoking, serum level of LDL-C, usage of
statins, plasma levels of Hs-CRP and APN, and Hs-CRP/
APN ratio were found significantly correlated with
CIMT as evaluated by multiple linear regression analysis.
Based on previous studies [17-21], it was reasonable to
explain the relationship between CIMT and cardiovascu-
lar risk factors such as smoking and LDL-C. Neverthe-
less, this was the first time we reported that Hs-CRP/
APN ratio was also significantly associated with CIMT.
Since plasma level of Hs-CRP and APN were affected
by many conditions as reported above, it was not pos-
sible for us to conclude that Hs-CRP/APN ratio was an
independent risk factor for CIMT progression. However,
because Hs-CRP/APN ratio could reflect a broader
spectrum of pathophysiological situation in terms of
both pro-inflammation and anti-inflammation, we be-
lieved that incorporating Hs-CRP/APN ratio into cardio-
vascular risk assessment was useful and helpful for










MI 0 0 1 3 NS
Stroke 0 1 2 3 NS
Death 0 0 0 0 NS
Denote: MI = myocardial infarction, NS = no significant.from our follow-up study was also supported for our rea-
soning. All participants were follow-up for 24 months and
underwent serials CIMT measurement every 6 months.
Results showed that the progression of CIMT was more
significant in the fourth quartile of Hs-CRP/APN ratio.
Additionally, the incidence of composite outcomes was
also higher in the fourth quartile than that of the other 3
lower quartiles, indicating that baseline Hs-CRP/APN
ratio was a useful parameter for helping us to identify
those who were at increased risk of cardiovascular events.
Finally, there were some limitations of current study.
First of all, the sample size was not large enough. Sec-
ondly, because current study was an observational study,
one could not make definite causal relationship between
Hs-CRP/APN ratio and CIMT progression and cardio-
vascular events. Additionally, there were some inhere
biases of observational studies which physicians should
bear in mind when interpreted current study.Conclusion
In conclusion, according to our current study, Hs-CRP/
APN ratio was a useful predictor for atherosclerosis
progression and clinical events. Because Hs-CRP/APN
ratio highly correlated with BMI, smoking, diabetic mel-
litus, usage of statins, and meanwhile baseline Hs-CRP/
APN ratio significantly correlated with CIMT progres-
sion and the incidence of clinical events, we considered
that further study should be focused on lifestyle modifi-
cation, glucose control and usage of statins so as to
find out whether tough control of these risks factors
and more intensive therapy with statins could improve
the Hs-CRP/APN ratio which finally results in better
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